Immunization Delivery Approaches
Immunization delivery approaches aim to ensure effective, safe vaccine administration across military operational environments. Emphasis is on thermostable formulations, needle‑free platforms (microneedle patches, jet injectors), mucosal/aerosol routes, and integrated logistics (cold-chain alternatives, sensors). These reduce logistical constraints and maintain protective immunity despite delayed evacuation or austere conditions.
Technical Challenges
Cold-chain dependence and vaccine thermostability limit reach in austere or prolonged-field-care environments.
Needle-based delivery risks (needlestick injury, sharps disposal) and requirement for trained vaccinators reduce rapid mass immunization capability.
Variable mucosal or aerosol delivery efficacy and reactogenicity complicate non-injectable vaccine strategies.
Regulatory complexity and lack of standardized field-stability assays slow translation of novel delivery platforms into operational use.
Emerging Opportunities
Truly thermostable vaccine formulations and dry-powder or lyophilized delivery systems validated for frontline use.
Easy-to-use, self-administered or minimally trained platforms (microneedle patches, auto-injectors) that are robust in austere settings.
Integrated sensors and validated stability biomarkers to verify potency in the field without complex laboratory support.
Standardized preclinical and clinical pathways for mucosal and needle-free technologies to accelerate DoD approval and deployment.
Current and Emerging Technologies in Immunization Delivery Approaches
Microneedle and dissolvable patch systems
Solid-state microneedle patches offer pain-free, low-burden delivery with potential for ambient stability and simplified logistics—ideal for self-administration and rapid mass immunization.
Thermostable formulations & dry-powder vaccines
Lyophilized and spray-dried vaccines, stabilizing excipients, and formulation science reduce or remove cold-chain needs, enabling storage and transport in extreme temperatures.
Mucosal, aerosol, and intranasal platforms
Targeted mucosal immunity via intranasal or aerosolized vaccines can confer frontline protection at pathogen entry sites; devices and formulations are emerging to improve dose consistency and safety.
Needle-free injectors and auto-injectors
Jet injectors, automated intramuscular devices, and single-use auto-injectors reduce sharps waste and enable administration by minimally trained personnel in mass or austere scenarios.
Integrated logistics: sensors, telemetry, and delivery drones
Cold-chain alternatives, embedded potency sensors, telemetry-enabled storage units, and autonomous delivery (drone/robotics) improve distribution speed and traceability to dispersed units.
Controlled-release implants and depot systems
Biodegradable depots and implantable delivery platforms offer sustained antigen release for prolonged protection where repeated access to care is not feasible.
Importance to Military Medicine
Force readiness and deployability
Rapid, reliable vaccination preserves unit readiness by preventing infectious disease outbreaks during deployment and training.
Prolonged and delayed evacuation scenarios
Field-stable and self-administered options enable maintained protective immunity when evacuation, resupply, or specialty care are delayed.
Austere logistics and mass-casualty response
Needle-free and thermostable solutions reduce logistical footprint and enable rapid, large-scale immunization in constrained environments.
Biodefense and outbreak mitigation
Flexible delivery platforms support rapid DoD response to emerging biological threats and mass prophylaxis without creating additional operational burdens.
Alignment with the MTEC Mission
Accelerates translation of DoD-relevant immunization technologies from prototype through field evaluation to operational use, consistent with MTEC’s mission to speed medical capabilities to Warfighters.
Leverages a broad portfolio—vaccines, delivery devices, logistics solutions—mirroring MTEC’s cross-disciplinary approach across infectious disease, prolonged care, and operational medicine.
Supports DoD priorities for readiness, austere operations, and biodefense by bridging engineering, formulation science, and clinical evaluation.
Promotes dual-use impact—military adoption accelerates civilian public-health benefits, aligning with MTEC’s commitment to benefit both Warfighters and the public.
Dual-Use (Military + Civilian) Applications
Mass immunization campaigns: Needle-free and patch technologies simplify large-scale vaccination during surge operations or pandemic response.
Outbreak and biodefense response: Rapid-deploy, thermostable vaccines and logistics reduce time-to-protection for exposed units and communities.
Rural and low-resource civilian health: Field-stable, simple-to-use platforms increase vaccine access for remote populations and disaster-affected areas.
Commercial translation: Technologies proven in military settings can transition to civilian markets, supporting manufacturing scale-up and regulatory approvals.
Explore MTEC Members with Immunization Delivery Approaches Capabilities
MTEC members bring multidisciplinary strengths—formulation science, device engineering, clinical trial networks, regulatory strategy, and manufacturing scale-up—to advance immunization delivery from concept to field deployment. Explore member profiles to identify partners with experience in thermostability testing, microneedle or aerosol platforms, logistics solutions, and DoD clinical evaluation pathways.
86 Members with Immunization Delivery Approaches capabilities.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The Precision Vaccines Program (PVP), based in the Department of Pediatrics at Boston Children’s Hospital, is an academic research initiative dedicated to discovering and developing next-generation vaccines tailored to vulnerable populations. PVP conducts both basic and translational research to create novel vaccines and therapeutics for diseases that disproportionately affect infants, older adults, and immunocompromised individuals. The program brings together experts in vaccinology, clinical trials, immunology, molecular biology, data management, biostatistics, bioinformatics, and systems biology, fostering international collaboration among academia, government, and industry to advance precision medicine in vaccinology.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
IntegerBio is at the forefront of Immunovirology, committed to combating serious viral diseases by pioneering the intersection of immunology and virology. The company focuses on developing broad multi-viral therapeutics using cutting-edge biology and data-focused approaches. Their mission is to harness the power of science to design therapeutics with durable responses across multiple viruses, aiming for a future without the fear of viral disease.
Kaléo is a global leader in drug-delivery device technology and auto-injector innovation, providing millions of patients with security and peace of mind. Our patented Aerio™ platform, with unmatched capabilities and human factors engineering, powers our portfolio of auto-injector products, as well as products under development for third parties.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
The University of Cincinnati Office of Research is a premier R1 urban research institution dedicated to advancing transformative knowledge and disruptive discoveries that address real-world challenges. Guided by its Research2030 strategic plan, the Office fosters interdisciplinary collaboration, supports innovative research initiatives, and connects industry, government, and community partners with UC's thought leaders. The Office accelerates economic growth and societal impact by investing in key research strengths such as analytics, cyber, robotics, sensors, skin science, adolescence, cancer, digital humanities, infectious diseases, medical devices, neuroscience, smart cities, sustainability, urban futures, and water. With a strong commitment to transparency, compliance, and research security, the Office provides comprehensive support for faculty, students, and staff throughout the research lifecycle, ensuring excellence and integrity in all scholarly activities. Specialized programs and support offices include biosafety, animal care, research integrity, cybersecurity, human research protection, defense research initiatives, government cost compliance, and radiation safety, all designed to uphold the highest standards of ethical, safe, and innovative research. The Office also keeps the community informed and engaged through its monthly 'Findings' newsletter, highlighting impactful research, partnerships, and opportunities.
The Nanovaccine Institute, established at Iowa State University in 2017, is a national transdisciplinary research consortium focused on advancing nano-based technologies to treat and prevent diseases. The institute aims to revolutionize public health outcomes through the design and promotion of nano-based vaccines and therapeutics.

University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.
Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.